FDA approvals: Pluvicto, Simtriyo and Ezplaz lead the July 24–31 ledger (2026)

At a glance

The strongest new signals in this week’s FDA record are a move earlier in prostate-cancer treatment for Pluvicto, the first U.S.-licensed freeze-dried plasma product, and a new ADHD medicine with a distinct pharmacologic profile. Simtriyo, Pluvicto, and Gwyn Lo are the week’s three drug actions; Ezplaz is the most consequential biologics license. The CBER log also lists approval letters for AREXVY, ADACEL, and Alphanate, but the accessible capture does not expose the exact supplement change for those three products.

The coverage window is July 24, 2026 at 5:00 p.m. through July 31, 2026 at 5:00 p.m. (UTC−05:00). Actions already covered in the July 24 issue are excluded. The device section is deliberately split: one substantive PMA approval, nine PMA supplement or process decisions, and 22 510(k)-file records. The 510(k) file captured for this issue contains decisions dated July 24–26; it is a monthly export, so the absence of July 27–31 records here is not evidence that no later device decisions occurred. 1 2 3

New drug approvals and indication expansion

Simtriyo: a new NDSRI for ADHD, with launch timing tied to DEA scheduling

FDA’s novel-drug table records Simtriyo (centanafadine) as approved on July 24 to treat attention-deficit/hyperactivity disorder. Otsuka’s announcement identifies the approved population as adults and pediatric patients 6 years and older who weigh at least 20 kg, using a once-daily extended-release capsule. 1 4

Otsuka describes centanafadine as the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), while also classifying it as a central-nervous-system stimulant. The application was supported by four pivotal Phase 3 randomized, double-blind, placebo-controlled trials across adults, adolescents, and children. The company reports statistically significant symptom improvement versus placebo, with improvement appearing as early as Week 1. Reported common adverse reactions varied by age: rash and decreased appetite in children; decreased appetite, nausea, rash, headache, and abdominal pain in adolescents; and headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea in adults. These clinical and safety details are company-reported; the FDA table itself is a concise approval listing. 4

Commercial read. Otsuka estimates that ADHD affects approximately 22.5 million children, adolescents, and adults in the United States. That is a sponsor market-size statement, not an independent market forecast. The near-term commercial constraint is unusually concrete: Otsuka expects availability later in 2026 after scheduling by the U.S. Drug Enforcement Administration. Simtriyo enters a large, established market with stimulant and non-stimulant alternatives, so the questions for investors and prescribers are not simply whether the mechanism is novel, but whether the once-daily profile, tolerability, and access pathway create meaningful use beyond existing options. The sources reviewed for this issue do not provide a launch price, independent peak-sales estimate, reimbursement terms, analyst revision, or share-price reaction.

Pluvicto: radioligand therapy moves into PSMA-positive mAPMN/S disease

On July 31, FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) from Novartis Pharmaceuticals Corporation in combination with androgen-receptor pathway inhibitor (ARPI) therapy for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer (mAPMN/S), the population previously referred to as metastatic hormone-sensitive prostate cancer. Patients must be selected using Locametz or another approved PSMA PET product based on tumor PSMA expression. 5

The decision was supported by PSMAddition (NCT04720157), a randomized, multicenter, open-label trial. The combination arm and ARPI-alone arm each included 572 patients. Pluvicto was administered at 7.4 GBq (200 mCi) every six weeks for six doses, or until progression or unacceptable toxicity. Radiographic progression-free survival improved significantly: median rPFS was not reached in either arm, but the hazard ratio was 0.72 (95% CI, 0.58–0.90; p=0.002). Overall-survival data were immature at the analysis used for approval. FDA lists warnings and precautions for radiation exposure, myelosuppression, renal toxicity, embryo-fetal toxicity, and infertility. 5

Clinical and commercial read. The important change is treatment position: a PSMA-directed radioligand is now approved in a less heavily treated metastatic setting, rather than being confined to a later-line population. The opportunity is therefore larger than a routine label clarification, but it comes with prerequisites that can limit real-world reach: PSMA PET selection, radiopharmaceutical handling, nuclear-medicine capacity, radiation-safety workflows, and coordination with an ARPI. The FDA evidence supports the rPFS benefit; it does not yet settle the overall-survival question, the size of the eligible U.S. population, or the reimbursement effect. No independent price, analyst forecast, or market-reaction evidence was captured for this issue.

Gwyn Lo: once-weekly contraception with a BMI limitation

Viatris announced FDA approval on July 29 of Gwyn Lo (norelgestromin and ethinyl estradiol transdermal system), a once-weekly combined hormonal contraceptive patch. The company says it is indicated for women of childbearing potential for whom a combined hormonal contraceptive is appropriate, with the approved population limited to BMI below 30 kg/m². The patch delivers norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. Because the FDA detail page was not recovered in this capture, these product, population, and clinical details are attributed to Viatris rather than presented as an FDA-page summary. 6

The company cites the Phase 3 Luminous Study (NCT05139121). It reports a Pearl Index of 4.14 (95% CI, 2.77–5.95), full detachment of 1.3% of 39,790 patches, and a decline in unscheduled bleeding or spotting from 34.5% in Cycle 1 to 20.0% by Cycle 13. Common adverse reactions reported by Viatris included application-site irritation, erythema, and pruritus, intercycle bleeding, heavy withdrawal bleeding, and nausea. The release says Gwyn Lo is contraindicated in women who smoke and are over 35 and in women with BMI at least 30 kg/m²; it also notes a potentially higher VTE risk above BMI 30. Commercial availability is expected later this year. 6

Commercial read. Gwyn Lo competes on dosing convenience and estrogen exposure in a mature contraceptive market, not on a new therapeutic category. The BMI restriction narrows the label relative to the total population seeking contraception and will be important in counseling and market sizing. The evidence reviewed here does not establish a launch price, payer coverage, expected share, or investor reaction.

Biologics: one new logistics platform, three limited-detail letters

Ezplaz: the approval is about plasma availability, not a universal replacement

On July 29, FDA licensed Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product licensed for use in the United States. The biologics license went to Vascular Solutions, LLC, a Teleflex subsidiary. Ezplaz is intended for transfusion in adults who need plasma when other plasma products are not available, including bleeding patients, patients needing massive transfusion, and certain patients bleeding while taking warfarin. 7

The product is derived from a single unit of fresh-frozen plasma collected from FDA-licensed blood establishments. It is available in Group AB and Group A with low-titer anti-B blood types, can be stored at room temperature, tolerates temperature fluctuations, and is rapidly reconstituted. The kit includes the plasma unit, 250 mL of sterile water for injection, a transfer set, and a transfusion set. FDA says the safety profile is consistent with other plasma products and reminds providers that transfusion risks still apply. 7

Clinical and commercial read. Ezplaz solves a logistics problem: frozen plasma requires cold-chain storage and thawing, while this product is designed for combat zones, disasters, rural settings, and other austere environments. Its label is expressly conditional on other plasma products being unavailable, so the first U.S. license should not be read as a replacement for conventional plasma in ordinary hospital workflows. The addressable opportunity is better understood as emergency and remote-care readiness; this issue has no public price, procurement forecast, reimbursement data, or investor-reaction evidence.

AREXVY, ADACEL, and Alphanate: confirmed letter postings, unresolved label changes

FDA’s CBER update lists three additional approval letters in the window. In each case, the existence and date of the letter are confirmed, but the specific supplement change was not recoverable from the accessible capture. That distinction matters: a letter posting is a regulatory event, not proof of a new indication or a change in patient eligibility.

Product	FDA letter date / CBER posting	Sponsor or manufacturer and baseline population	What can be said safely
AREXVY	July 27 letter; listed by CBER on July 28	GlaxoSmithKline Biologicals SA. FDA’s product page describes active immunization to prevent RSV lower-respiratory-tract disease in people 60+ and people 18–59 at increased risk.	The July 27 supplement is confirmed; the exact approved change is not characterized here. 8 9
ADACEL	July 30 letter; listed by CBER on July 31	FDA’s public parent guide describes Adacel as approved for people ages 10–64 and notes use during the third trimester of pregnancy to help prevent pertussis in infants. The manufacturer and the supplement’s exact target population were not recoverable from this capture.	The letter posting is confirmed; no new age group, pregnancy claim, or other label change is inferred. 10 11
Alphanate	July 31 letter; listed by CBER on July 31	Grifols Biologicals Inc. FDA lists treatment and prevention of bleeding and perioperative management in hemophilia A, plus perioperative management in specified von Willebrand disease populations.	The letter posting is confirmed; the exact supplement change is not characterized here. 12 13

For clinicians and patient advocates, the practical next step is to open the letter and updated package insert before treating any of these three postings as a change in eligibility, dosing, safety language, or access. For investors, these items should remain in the “follow-up” bucket until the supplement’s scope is known.

Medical devices: one substantive PMA, then a broad ledger

SimpleScreen CRC: a PMA approval for average-risk screening adults 45 and older

FDA’s PMA record shows P250029 approved on July 24 for Freenome, LLC’s SimpleScreen CRC. The device is a qualitative in-vitro diagnostic test that detects molecular signals associated with colorectal cancer using circulating cell-free DNA from plasma collected in the SimpleScreen CRC blood-collection kit. It is indicated for colorectal-cancer screening in adults 45 and older at average risk. A positive result must be followed by colonoscopy, and FDA explicitly says the test is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. The record links to clinical trial NCT04369053 but does not provide a performance result in the accessible approval-page text. 14

Commercial read. SimpleScreen enters a large screening workflow, but its commercial value depends on more than the PMA headline: clinician ordering, laboratory logistics, follow-up colonoscopy capacity, payer policy, and patient adherence after a positive result. Its competitive frame includes existing colonoscopy and noninvasive screening options. The FDA label’s “not a replacement” language is the key boundary for practice and patient communication; no independent market-size estimate, launch price, reimbursement terms, or investor reaction was captured.

PMA supplement and process ledger

The FDA PMA export captured for this run contains ten in-window records. Only SimpleScreen is a new main PMA approval in the table below. The other nine are supplements or 30-day notices: they may matter for manufacturing continuity, software, post-approval evidence, or product configuration, but they are not new clinical indications. 15

PMA record	Sponsor	Device	Decision date	Track / change recorded
P250029	Freenome, LLC	SimpleScreen CRC	07/24/2026	APPR; new PMA for average-risk colorectal-cancer screening in adults 45+
P160032/S014	Defibtech, LLC	Lifeline/ReviveR AED series	07/24/2026	APPR; extends the DDU-2000 series to VIEW 2 models and a Universal Pads accessory
P250033/S002	Endospan, Ltd.	NEXUS Aortic Arch Stent Graft System	07/24/2026	APPR; post-approval study protocol
P190006/S110	Boston Scientific	Axonics Sacral Neuromodulation System	07/24/2026	APPR; minor software update to the External Trial Stimulator
P180046/S110	Boston Scientific	Axonics Sacral Neuromodulation System	07/24/2026	APPR; minor software update
P150004/S099	Abbott Medical	DRG IPG	07/26/2026	OK30; alternate drop-in diode components in IPG circuit boards
P110005/S015	IBSA	Gelsyn-3	07/24/2026	OK30; new dispensing area for raw materials at an Italian facility
P010032/S259	Abbott Medical	SCS IPG	07/26/2026	OK30; alternate diode components
P140009/S138	Abbott Medical	DBS IPG	07/26/2026	OK30; alternate diode components
P070026/S128	DePuy Orthopaedics	CERAMAX Ceramic Total Hip System	07/24/2026	OK30; automated Air Gage inspection and data capture for Summit Hip Stem components

510(k) and De Novo records captured through July 26

The monthly 510(k) file is useful for identifying releasable decisions, applicants, device names, dates, product codes, and review panels. It does not carry the full intended-use narrative from each decision summary. The table is therefore a regulatory ledger, not a clinical-performance or sales ranking. Item-level intended use, predicate comparison, safety data, and labeling should be reviewed in the individual FDA record before making an investment or practice decision. 2 16

FDA number	Applicant	Device name	Decision date	Submission type / panel
K252370	Free Wheelchair Mission	GEN 4 JOY Wheelchair	07/24/2026	Traditional / PM
K253206	Meticuly Co., Ltd.	METICULY Patient-specific CMF solution	07/25/2026	Traditional / DE
K253452	Rivanna Medical, Inc.	Accuro 3S	07/24/2026	Traditional / RA
K253943	Zavation Medical Products, LLC	Tiger 2 System	07/24/2026	Traditional / OR
K254180	LIMIS Development B.V.	PerfusiX-Imaging	07/24/2026	Traditional / GU
K260192	ROPCA ApS	DIANA	07/24/2026	Traditional / RA
K260362	MANTIZ Co., Ltd.	QUATTRO Spinal System; QUATTRO-GADGET Spinal System	07/24/2026	Traditional / OR
K260598	iSMART Developments, Ltd.	5 Wavelength LED Facemask (TN2508)	07/24/2026	Traditional / SU
K260948	Wavepulse Healthcare Technology	Air Compression Massager (EP30B001 I)	07/24/2026	Traditional / PM
K261024	THINK Surgical, Inc.	TMINI Miniature Robotic System	07/24/2026	Traditional / OR
K261027	Hycor Biomedical	NOVEOS Specific IgE reagents and peanut/tree-nut capture reagents	07/24/2026	Traditional / IM
K261267	Fresenius Medical Care Renal Therapies Group	Careflux H60, H70, and V500	07/24/2026	Traditional / GU
K261349	Airs Medical, Inc.	SwiftMR	07/24/2026	Traditional / RA
K261364	Siemens Healthcare Diagnostics	Atellica CH Acetaminophen 2 (ACTM)	07/24/2026	Traditional / CH
K261367	Corsano Health B.V.	Corsano CardioWatch 287-2 System	07/26/2026	Traditional / NE
K261488	Boston Scientific Corporation	OBSIDIO Conformable Embolic	07/24/2026	Traditional / CV
K261849	Luma Vision Limited	VERAFEYE Imaging Catheter (VF-VIC-002)	07/24/2026	Special / CV
K262121	SurGenTec, LLC	Ion-L Navigated Instruments	07/24/2026	Special / OR
K262152	VISION MEDICAL Co., Ltd.	VS-370CF, VS-370CT	07/24/2026	Traditional / GU
K262290	Osteoremedies, LLC	REMEDY POLY+PLUS SNAP FIT Acetabular Cup	07/24/2026	Special / OR
K262294	Philips Medical Systems Nederland B.V.	dS FootAnkle, dS HiRes Hand/Wrist, and dS Small Extremity coil systems	07/24/2026	Special / RA
K262383	Nucletron B.V.	LumenCare Azure	07/24/2026	Special / RA

The captured device set is broad rather than concentrated: it spans mobility equipment, patient-specific cranio-maxillofacial solutions, surgical and robotic systems, imaging and MRI accessories, diagnostics, renal therapies, cardiovascular devices, orthopedics, and home or wellness-oriented products. That breadth is useful for monitoring regulatory throughput, but the file alone cannot tell an investor which products will launch, what they will cost, or whether clinicians will adopt them.

What matters next

Simtriyo: DEA scheduling, launch price, payer treatment, and real-world tolerability will determine whether a new NDSRI becomes a meaningful ADHD option rather than simply another approved product.
Pluvicto: PSMA-PET capacity, radioligand treatment infrastructure, payer coverage, and mature overall-survival data will determine how far the earlier-line label travels into routine practice.
Gwyn Lo: commercial availability later this year and the practical effect of its BMI limitation will matter more than the approval announcement for market reach.
Ezplaz: procurement and field deployment will show whether room-temperature, rapidly reconstituted plasma changes emergency readiness outside conventional hospitals.
SimpleScreen: follow-up colonoscopy pathways and reimbursement will determine whether a blood-based screening test improves completion of the full screening cascade.
Devices: the next diligence step is individual-record review. The 510(k) monthly export stops at July 26 in this capture and does not provide intended-use narratives; the PMA ledger distinguishes one substantive approval from process and supplement actions.

No reliable contemporaneous independent analyst revisions, stock-price reaction, launch pricing, reimbursement terms, or peak-sales forecasts were captured for this edition. Where commercial numbers appear, they are explicitly identified as sponsor statements or as qualitative implications of the FDA record.

FDA approvals: Pluvicto, Simtriyo and Ezplaz lead the July 24–31 ledger